Bristol-Myers Squibb and Pfizer Alliance urge people to 'Tune in to AFib, Take Note of Stroke Risk'

Bristol-Myers SquibbThe Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched 'Tune in to AFib, Take Note of Stroke Risk' to educate the estimated nearly seven million Americans in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke. People with AFib are five times more likely to have a stroke than those who do not have the condition, and these strokes are more severe and more likely to be fatal than strokes not associated with AFib. Through music, the program aims to inspire people living with AFib, the most common type of irregular heartbeat, to work with their doctor to help reduce their risk of stroke.

Afternoon host of New York’s Classic Rock Station Q104.3 Ken Dashow knows how important it is for people to ‘tune in' to AFib. "When one of my closest friends told me he had AFib and explained the associated increased stroke risk, I had to find a way to use my voice and get involved," said Dashow. "In my more than 30 years of experience in the music industry, I've learned that music has a powerful ability to inspire action. Through 'Tune in to AFib,' we're urging people with AFib to take action by talking to their doctor about how to reduce their stroke risk."

'Tune in to AFib' includes an educational website, TuneintoAFib.com, where people can view exclusive concert footage of Southside Johnny and the Asbury Jukes, hear from Ken Dashow and learn more about AFib and its associated increased stroke risk. The program also encourages people to take an online quiz to determine how 'in tune' they are with AFib and stroke risk. Those who complete the quiz can access an additional exclusive music video and the Bristol-Myers Squibb and Pfizer Alliance will make a $1 donation to the National Stroke Association for each person who completes the quiz, up to $30,000.

With AFib, the top chambers of the heart ("the atria") do not contract properly to push blood through the heart. As a result, some blood remains in the top chambers, which can pool, and clots may form. These clots can travel to the brain, blocking or limiting blood flow, and may result in a stroke.

"Many people with AFib not caused by a heart valve problem don’t have any symptoms and are unaware that the condition is the cause of approximately 15 percent of all strokes," said David Frankel, M.D., Director of the Cardiac Electrophysiology Fellowship Program and Assistant Professor of Medicine at Penn Medicine. "'Tune in to AFib' encourages these people to increase their knowledge of this serious medical condition, recognize their increased stroke risk and work with their doctor to help reduce this risk."

To learn more, visit TuneintoAFib.com.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Pfizer Inc.: Working together for a healthier world ®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...